Trial Profile
A Pilot Study of Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatric and Young Adult Patients With Relapsed and Refractory Solid Tumors or Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 30 Jan 2023 Planned primary completion date changed from 12 Jan 2023 to 15 Jun 2024.
- 24 May 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2020 Planned number of patients changed from 15 to 21.